Sector News

Alexion fortifies rare blood disorder drugs business with Achillion deal

October 16, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Alexion Pharmaceuticals Inc on Wednesday agreed to buy smaller biotech Achillion Pharmaceuticals Inc in a deal initially valued at $930 million, as the company looks to retain its leadership in treating certain rare blood disorders.

Alexion, which is paying a 73% premium, is eyeing Achillion’s two experimental treatments for the rare blood disorder, paroxysmal nocturnal hemoglobinuria (PNH), a market it has dominated with its flagship drug Soliris.

The drug now faces patent challenges, and the company is fighting back by converting patients to a Soliris successor drug called Ultomiris, which won U.S. approval last year, and analysts said Wednesday’s deal will support the strategy.

“The transaction has strong strategic rationale as a defensive play for Alexion versus competitors,” Evercore ISI analyst Josh Schimmer said, adding that the deal would allow Alexion to preserve Ultomiris’ market share and defend its franchise.

Soliris, which also treats atypical hemolytic uremic syndrome, recorded sales of $3.56 billion last year, accounting for about 86% of the drugmaker’s total revenue.

But the “obvious, and quite significant overlap in therapeutic focus” between the two companies could invite a challenge from the Federal Trade Commission (FTC), according to SVB Leerink analyst Geoffrey Porges.

Alexion Chief Financial Officer Aradhana Sarin acknowledged such concerns during a conference call with analysts.

“We’ll just have to go through the FTC process and address the questions the FTC raises,” she said.

Achillion shareholders will receive $6.30 per share held and are eligible to get another $2 per share subject to certain considerations, the companies said. The deal is expected to close in the first half of 2020.

Shares of Achillion surged 74% to $6.35, while Alexion stock dipped 1.8% to $102.98.

PNH, which affects 1-1.5 persons per million of the population and is primarily a disease of younger adults, is a rare, life-threatening disorder in which red blood cells are prematurely destroyed by the patient’s immune system.

For Achillion, which shifted focus to treating blood disorders after Johnson & Johnson (JNJ.N) backed out of a collaboration to develop a hepatitis C treatment in 2017, the deal is a “big win”, said SVB Leerink analyst Joseph Schwartz.

Alexion, which is rebuilding after a series of setbacks in the past few years, is also beefing up its portfolio of drugs for other rare diseases.

The company bought Sweden’s Wilson Therapeutics for $855 million and followed that up with the purchase of Syntimmune for a total value of up to $1.2 billion.

By Tamara Mathias

Source: Reuters

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 14, 2019

UnitedHealth adds new C-suite member from Lockheed Martin

Life sciences

LinkedIn Twitter FacebookUnitedHealth Group Inc. has hired Patricia Lewis as its new chief human resources officer. She’ll serve in the office of the chief executive, the company said in an email. […]

November 13, 2019

Novartis’ Sandoz to acquire Aspen Japan for $331m

Life sciences

LinkedIn Twitter FacebookNovartis subsidiary Sandoz has signed an agreement to buy Aspen Japan operations and related intellectual property from Aspen Global for an upfront payment of €300m ($331m) in cash. […]

November 12, 2019

Amgen to cut 149 staff in retreat from neuroscience R&D

Life sciences

LinkedIn Twitter FacebookAmgen has given notice of its intent to lay off 149 people at its Cambridge, Massachusetts, operation by the end of the year. The notice comes weeks after […]

Subscribe to our Weekly Newsletter

We're easy to reach